Quick Answer
Sigyn Therapeutics, Inc. reported R&D Expense of $773.3 thousand for fiscal year 2024.
Sigyn Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $773.3K | -3.1% |
| 2023 | $798.2K | +21.4% |
| 2022 | $657.7K | -10.4% |
| 2021 | $734.0K | +75.0% |
| 2020 | $419.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.7K | -85.6% | +296.7% |
| June 30, 2025 | $7.5K | -96.9% | -15.4% |
| March 31, 2025 | $8.8K | -96.2% | -95.7% |
| September 30, 2024 | $206.2K | -4.2% | -14.3% |
| June 30, 2024 | $240.4K | +9.7% | +3.4% |
| March 31, 2024 | $232.6K | +57.3% | +8.1% |
| September 30, 2023 | $215.2K | +60.9% | -1.8% |
| June 30, 2023 | $219.2K | +41.7% | +48.2% |
- Sigyn Therapeutics, Inc. showed a decrease of -3.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, Sigyn Therapeutics, Inc.’s r&d expense has grown by 84.4% (from $419.4 thousand to $773.3 thousand).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: